EORTC-1537-COBRA: Very Early PET-Guided Therapy Switch Achieves 89.5% 2-Year mPFS in Advanced-Stage Hodgkin Lymphoma
核心洞察
The phase II EORTC-1537-COBRA trial demonstrated a 2-year modified progression-free survival of 89.5% using very early PET-guided treatment adaptation after a single cycle of A-AVD in advanced-stage cHL.
PET1-negative patients (60%) continued A-AVD, while PET1-positive patients (40%) switched to BrECADD, achieving 2-year mPFS rates of 88.3% and 91.3%, respectively.
The 2-year overall survival was 100% at a median follow-up of 30.1 months, with no treatment-related deaths reported.
A single-arm, multicenter, phase II trial has shown that adapting treatment based on very early [18F]FDG-PET–CT findings after just one cycle of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A-AVD) yields a 2-year modified progression-free survival (mPFS) of 89.5% in adults with previously untreated, advanced-stage classical Hodgkin lymphoma (搜索) (cHL). The results, published in The Lancet Haematology by Hutchings et al., met the study's predefined success criterion.
The EORTC-1537-COBRA trial (NCT03517137) enrolled patients with advanced-stage cHL and used PET1 imaging after a single cycle of A-AVD to guide subsequent therapy. Among 150 patients, 90 (60%) were PET1-negative and continued A-AVD, while 60 (40%) were PET1-positive and switched to an intensified regimen of brentuximab vedotin plus etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD).
Survival Outcomes and PET-Stratified Results
At a median follow-up of 30.1 months, the 2-year mPFS for the evaluable population (n=145) was 89.5% (80% CI, 85.7–92.4). The 2-year overall survival (OS) was 100%, with no treatment-related deaths observed during the study period.
When analyzed by PET1 status, the 2-year mPFS was 88.3% (95% CI, 79.4–93.5) among patients who remained on A-AVD after a negative PET1 scan. For those who were PET1-positive and switched to BrECADD, the 2-year mPFS was 91.3% (95% CI, 80.3–96.3), indicating that early intensification may effectively salvage patients with a suboptimal initial metabolic response.
Biomarker Findings
The study also explored the role of serum thymus and activation-regulated chemokine (sTARC) as a potential biomarker. A positive sTARC level after one cycle of therapy was significantly associated with PET1 positivity, with an odds ratio of 2.3 (95% CI, 1.0–5.2; p=0.048). This finding suggests that sTARC measurement could complement imaging-based response assessment in guiding early treatment decisions.
Safety Profile
Grade 3–4 adverse events occurred in 63% of patients. The most frequently reported high-grade toxicities were neutropenia (35%) and anemia (12%). Serious adverse events were documented in 30% of participants. Importantly, no treatment-related deaths were recorded, supporting the tolerability of both the A-AVD and BrECADD regimens in this patient population.
Clinical Implications
The COBRA trial represents one of the earliest PET-adapted strategies evaluated in advanced-stage cHL, using response assessment after a single cycle rather than the more conventional two-cycle interim PET. The high 2-year OS of 100% and the ability to intensify therapy early for PET1-positive patients underscore the potential of this approach to optimize outcomes while potentially sparing PET1-negative patients from unnecessary treatment escalation.
These findings align with the broader evolution of Hodgkin lymphoma management toward risk-adapted and PET-guided strategies, as reflected in recent clinical practice guidelines that recommend PET-directed treatment decisions across disease stages.